We recently published a list of Jim Cramer Says Trump’s Tariff Strategy Is Working & Discusses These 11 Stocks. In this ...

J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...

Johnson & Johnson (NYSE:JNJ – Get Free Report) has received a consensus rating of “Moderate Buy” from the eighteen research ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

强生(JNJ.US)周五宣布，计划在未来四年将其在美国的投资增加到550亿美元以上，比前四年增长25%。 除了位于北卡罗来纳州威尔逊的工厂外，该公司增加的投资还涵盖三个新的先进制造工厂，以及其创新医学和医疗技术业务的多个现有工厂的扩建。 强生还计划对研发基础设施进行大量投资，并加大技术投资以加快药物发现和开发。 随着投资的增加，强生对美国经济的影响将在目前预计的每年超过1000亿美元的基础上进一步 ...

The latest trading day saw Johnson & Johnson (JNJ) settling at $163.29, representing a -0.21% change from its previous close.

JNJ is a #3 (Hold) on the Zacks Rank ... For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year.

JOHNSON & JOHNSON (JNJ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s ...

智通财经APP获悉，2025年3月17日，强生 (JNJ.US)在Clinicaltrials.gov网站上注册了IL-23R口服环肽抑制剂JNJ-2113 (Icotrokinra)治疗银屑病关节炎的三期临床试验ICONIC-PsA 1。该三期临床试验计划入组540例银屑病关节炎患者，预计2026年初步完成。

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions. Three Motley Fool contr ...